IR-820 (New Indocyanine Green): Precision Near-Infrared Imaging for Biomedical Research

Executive Summary: IR-820 (New Indocyanine Green) is a near-infrared (NIR) dye with strong absorption and emission in the NIR region, enabling real-time visualization of vasculature and tumor tissues in vivo [product information]. With a molecular weight of 849.47 and formula C₄₆H₅₀ClN₂NaO₆S₂, it exhibits excellent photostability and NIR fluorescence, supporting sensitive detection of diseased tissues (Hao et al., 2023). IR-820 is widely utilized in vascular and tumor imaging workflows, with performance benchmarks established in syngeneic animal models. It is provided by APExBIO for research purposes only and must be handled under recommended storage conditions to maintain dye integrity.

Biological Rationale

Near-infrared fluorescence imaging is a cornerstone of preclinical research, as it allows deep-tissue visualization with minimal autofluorescence and enhanced signal-to-noise ratios. The absorption and emission peaks of IR-820 (New Indocyanine Green) fall within the NIR window (typically 700–900 nm), optimizing tissue penetration and minimizing background interference [see protocol guide]. This enables precise mapping of vasculature and tumor boundaries in living animal models, supporting studies in oncology, cardiovascular biology, and pharmacokinetics. The dye is especially valuable for quantifying diseased tissue burden, tracking dynamic vascular changes, and evaluating nanoparticle distribution in vivo [see innovations article]. This article extends prior internal protocols by emphasizing standardized benchmarks and evidence-based limitations.

Mechanism of Action of IR-820 (New Indocyanine Green)

IR-820 is structurally related to classic indocyanine green dyes but features enhanced NIR absorbance and emission. Upon intravenous administration, IR-820 binds to plasma proteins, remaining predominantly within the vasculature, which facilitates its use as a blood pool contrast agent. When excited by NIR laser sources (commonly 780–808 nm), IR-820 emits fluorescence detectable by standard NIR imaging systems. This property enables sensitive detection of vascular integrity, tumor perfusion, and tissue permeability in real time (Hao et al., 2023). In nanoparticle-enabled therapies, IR-820 analogs can be encapsulated to monitor both drug delivery and photothermal responses.

Evidence & Benchmarks

• IR-820 achieves high signal-to-background ratios for vascular and tumor imaging in murine models, outperforming traditional visible-range dyes under NIR excitation (Hao et al., 2023).
• The dye's absorption and emission maxima (typically ~790 nm and ~820 nm, respectively) enable deep tissue imaging up to several centimeters in small animal models [product information].
• Photostability studies show IR-820 maintains fluorescence intensity after repeated NIR laser exposure, critical for longitudinal imaging [protocol guide].
• When incorporated into MOF nanoparticles, indocyanine green dyes support both photothermal ablation and immune activation, enabling dual-modal therapy in melanoma models (Hao et al., 2023).
• APExBIO's IR-820 (C8228) is shipped with blue or dry ice to preserve dye stability, and is recommended for scientific research use only [product information].

Applications, Limits & Misconceptions

IR-820 is primarily designed for animal research, including:

• Vascular imaging agent: Enables mapping of blood flow and vessel integrity in vivo.
• Tumor imaging dye: Permits quantification and localization of solid tumors in preclinical models.
• Diseased tissue quantification: Supports longitudinal studies of tissue pathology and therapy response.
• Nanomedicine tracking: Used to monitor distribution of drug-loaded nanoparticles in combination therapies.

Despite its versatility, IR-820 is not approved for human diagnostic or therapeutic use and is unsuitable for applications outside of controlled laboratory studies. This article clarifies previous workflow-focused guides by emphasizing constraints and validated endpoints [applied protocols].

Common Pitfalls or Misconceptions

• IR-820 solutions are unstable over prolonged storage; prepare fresh aliquots for each experiment to avoid degradation.
• The dye is not suitable for clinical diagnostics or direct human use.
• Photobleaching can occur under high-intensity illumination—optimize laser power and exposure time accordingly.
• IR-820 is not a substitute for immune or targeted probes; it functions as a general blood pool agent.
• Background signal may increase in highly autofluorescent tissues; select appropriate imaging filters.

Workflow Integration & Parameters

Successful use of IR-820 (New Indocyanine Green, C8228) in in vivo imaging requires attention to protocol details. Researchers are advised to:

Protocol Parameters

• Preparation: Dissolve IR-820 powder in sterile PBS or saline immediately before use; avoid long-term storage of stock solutions.
• Dosage: Typical animal imaging doses are 0.5–2 mg/kg body weight, administered intravenously; confirm with pilot titration.
• Imaging: Excite at 780–808 nm and collect emission at 820–840 nm for optimal tissue contrast.
• Storage: Store dry powder at 4°C, tightly sealed and desiccated, as per APExBIO guidance.
• Shipping: Receive product shipped on blue/dry ice to maintain stability, especially in warmer climates.

For detailed troubleshooting and workflow adaptation, see the guide on scenario-driven imaging protocols, which this article updates with current evidence and validated parameter recommendations.

Conclusion & Outlook

IR-820 (New Indocyanine Green) from APExBIO has established itself as a robust near-infrared imaging agent for preclinical vascular and tumor research. Its strong fluorescence, compatibility with standard NIR imaging systems, and validated stability in animal models make it a preferred tool for quantification of pathologic tissue. Ongoing studies employing indocyanine green analogs in nanoparticle-enabled photothermal and immunotherapy demonstrate the expanding utility of such dyes in advanced cancer research (Hao et al., 2023). Future improvements will likely focus on enhancing target specificity and reducing background, but current evidence strongly supports IR-820’s role as a reliable research reagent.